Skip to main content
. 2015 Jul 31;126(16):1893–1901. doi: 10.1182/blood-2015-03-632430

Table 4.

One- and 2-year rates of PFS, OS, and patients remaining treatment-free (intent-to-treat population)

Outcome % (95% CI) Hazard ratio* (95% CI) P
VR-CAP, n = 84 R-CHOP, n = 80
PFS rate
 1-y 80.0 (69.0-87.5) 82.3 (71.4-89.3) 1.12 (0.57-2.20) .76
 2-y 76.2 (64.2-84.7) 77.1 (65.1-85.4)
OS rate
 1-y 91.2 (82.3-95.7) 85.9 (76.0-92.0) 0.89 (0.44-1.81) .75
 2-y 80.1 (69.0-87.5) 79.0 (67.9-86.6)
Treatment-free rate§
 1-y 70.6 (59.2-79.4) 78.4 (67.2-86.2) 1.25 (0.69-2.24) .49
 2-y 69.3 (57.8-78.3) 71.8 (59.6-80.9)
*

R-CHOP vs VR-CAP; a HR of <1 indicates an advantage for VR-CAP.

Based on the log-rank test (stratified by International Prognostic Index score).

PFS rate by Independent Radiology Review Committee assessment.

§

Patients who had not received subsequent lymphoma therapy or had not died due to progressive disease.